Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Psychosis Clinical Trials

A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (81) clinical trials

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

The main purpose of this study is to evaluate the efficacy of the study drug known as LY3314814 in participants with mild Alzheimer's disease (AD) dementia.

Phase

The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.

Phase

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

Phase

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia

Phase

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUNCTIVE PIMAVANSERIN FOR THE TREATMENT OF SCHIZOPHRENIA

Phase

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophre

Phase

INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, FIXED-DOSE STUDY OF Lu AF35700 IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA

Phase